East Meets West
Pharmaceutical Executive
Croatia's Pliva Pharmaceuticals is the first eastern European pharma company to make a US acquisition. Pliva paid $153 million for New Jersey-based Sobel Holdings,
Croatia's Pliva Pharmaceuticals is the first eastern European pharma company to make a US acquisition. Pliva paid $153 million for New Jersey-based Sobel Holdings, which owns Sidmak, a generics maker, and Odyssey, a specialty brand-name pharma company with products such as Urecholine (bethanechol) for non-obstructive urinary retention; Vivactil (protryptylline) and Surmontil (trimipramine) for depression; Antabuse (disulfiram) for alcohol abuse; Nystatin vaginal tablets (for candidiasis); and Custodol HTK solution for the preservation of donor organs.
In addition to the company's product rights and trademarks, the deal gives Pliva an established US distribution network and a product development and manufacturing plant in East Hanover, New Jersey.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
